ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients. In January 2017, Takeda announced it would acquire ARIAD for $5.2 billion, expanding the company's oncology and hematology business. On February 16, 2017, Takeda Pharmaceuticals, Ltd. announced it had completed its acquisition of ARIAD and incorporated ARIAD into Takeda Oncology.

Property Value
dbo:abstract
  • ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients. ARIAD’s most prominent drug discoveries include Iclusig, designed for patients with all forms of Philadelphia chromosome-positive [Ph+] chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) who are resistant to or unable to tolerate other tyrosine kinase inhibitors, and brigatinib, a lung cancer drug which has completed its registration trial in ALK fusion driven non-small cell lung cancer as of June 2016 and was approved in the U.S. in April 2017. In January 2017, Takeda announced it would acquire ARIAD for $5.2 billion, expanding the company's oncology and hematology business. On February 16, 2017, Takeda Pharmaceuticals, Ltd. announced it had completed its acquisition of ARIAD and incorporated ARIAD into Takeda Oncology. (en)
dbo:assets
  • 546.69
dbo:fate
  • Merged withTakeda Pharmaceuticals (en)
dbo:foundingYear
  • 1991-01-01 (xsd:date)
dbo:industry
dbo:keyPerson
dbo:location
dbo:numberOfEmployees
  • 380 (xsd:integer)
dbo:product
dbo:revenue
  • 118.8
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 20737471 (xsd:integer)
dbo:wikiPageLength
  • 16048 (xsd:integer)
dbo:wikiPageRevisionID
  • 961126898 (xsd:integer)
dbp:assets
  • US$546.69M (en)
dbp:defunct
  • 2017 (xsd:integer)
dbp:fate
  • Merged with Takeda Pharmaceuticals (en)
dbp:foundation
  • 1991 (xsd:integer)
dbp:homepage
dbp:industry
dbp:keyPeople
  • Chairman of the Board (en)
  • President of Research and Development and Chief Scientific Officer (en)
  • Alex Denner, (en)
  • Ed Fitzgerald, (en)
  • Founder, chairman, and CEO Emeritus (en)
  • Harvey Berger, (en)
  • Marty Duvall, (en)
  • Timothy P. Clackson, (en)
dbp:location
dbp:logo
  • ARIAD logo.png (en)
dbp:logoSize
  • 151 (xsd:integer)
dbp:name
  • ARIAD Pharmaceuticals, Inc. (en)
dbp:netIncome
  • US$ (en)
dbp:numEmployees
  • 380 (xsd:integer)
dbp:operatingIncome
  • US$ (en)
dbp:products
dbp:revenue
  • US$118.8M (en)
dbp:tradedAs
  • NASDAQ:ARIA (en)
dbp:type
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients. In January 2017, Takeda announced it would acquire ARIAD for $5.2 billion, expanding the company's oncology and hematology business. On February 16, 2017, Takeda Pharmaceuticals, Ltd. announced it had completed its acquisition of ARIAD and incorporated ARIAD into Takeda Oncology. (en)
rdfs:label
  • ARIAD Pharmaceuticals (en)
owl:sameAs
skos:closeMatch
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • ARIAD Pharmaceuticals, Inc. (en)
is dbo:institution of
is dbo:wikiPageRedirects of
is foaf:primaryTopic of